Home
About
Overview
Management Team
Board of Directors
Medical Advisory Board
Product Pipeline
Overview
APX3330
APX2009
Phentolamine Ophthalmic Solution 0.75%
Scientific Posters and Publications
Clinical Trials
Overview
VEGA-2 Pivotal Phase 3 Trial of Phentolamine Ophthalmic Solution 0.75% in Presbyopia
Completed
ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330
Completed
MIRA-4: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects
Completed
MIRA-3
Completed
MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol
Completed
LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol
Completed
VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine
Completed
Partnerships
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
Investors
Overview
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
Contact
Careers
Ocuphire in the News
News & Media
News & Media
Press Releases
Presentations
Events
Ocuphire in the News
MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference
Feb 22, 2023
Oral diabetic retinopathy treatment fails to meet primary endpoint in phase 2 trial
Jan 27, 2023
Top five refractive surgery items from 2022
Dec 27, 2022
Pipeline update from Ocuphire
Dec 26, 2022
Phentolamine improved distance-corrected near visual acuity
Dec 20, 2022
Treatment of Presbyopia: One of Several Potential Indications for Nyxol
Dec 1, 2022
Ocuphire partners with Viatris for marketing, commercialization of Nyxol eye drop
Nov 19, 2022
Presbyopia Physician November eUpdate
Nov 10, 2022
Ocuphire initiates Global License Agreement for Nyxol eye drops across 3 indications
Nov 8, 2022
Ocuphire reaches license agreement for the development and commercialization of Nyxol
Nov 8, 2022
« Previous
1
2
3
4
5
Next »
